Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital

被引:10
作者
Chan, Thomas S. Y. [1 ]
Marcella, Stephen W. [2 ]
Gill, Harinder [1 ]
Hwang, Yu-Yan [1 ]
Kwong, Yok-Lam [1 ]
机构
[1] Queen Mary Hosp, Div Haematol & Haematol Oncol, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Merck & Co Inc, Outcomes Res CORE, Kenilworth, NJ USA
关键词
Posaconazole; Fluconazole; Itraconazole; Antifungal prophylaxis; Neutropenia; Cost-effective; Cost-saving; RISK NEUTROPENIC PATIENTS; STANDARD AZOLE THERAPY; ECONOMIC-EVALUATION; PROLONGED NEUTROPENIA; PROPHYLAXIS; INFECTIONS; SOCIETY;
D O I
10.3111/13696998.2015.1094477
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background:Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients. Whether the higher cost of posaconazole is offset by decreases in IFDs in a given institute requires cost-effective analysis encompassing the spectrum of IFDs and socioeconomic factors specific to that geographic area.Methods:This study performed a cost-effective analysis of posaconazole prophylaxis for IFDs in an Asian teaching hospital, employing decision modeling and data of IFDs and medication costs specific to the institute, in neutropenic patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).Results:In the cost-effectiveness analysis, the higher cost of posaconazole was partially offset by a reduction in the cost of treating IFDs that were prevented, resulting in an incremental cost of 125,954 Hong Kong dollars/16,148 USD per IFD avoided. Over a lifetime horizon, assuming same case fatality rate of IFDs in both groups, use of posaconazole results in 0.07 discounted life years saved. This corresponds to an incremental cost of 116,023 HKD/14,875 USD per life year saved. This incremental cost per life year saved in posaconazole prophylaxis fulfilled the World Health Organization defined threshold for cost-effectiveness.Conclusion:Posaconazole prophylaxis was cost-effective in Hong Kong.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 25 条
[1]  
[Anonymous], 2013, SEER Cancer Statistics Review (CSR) 1975- 2010
[2]  
[Anonymous], 2006, SEER Cancer Statistics Review 1975-2003
[3]  
Census and Statistics Department The Government of Hong Kong SAR, NAT INC
[4]   Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital [J].
Chan, T. S. Y. ;
Hwang, Y. -Y. ;
Gill, H. ;
Cheung, W. W. W. ;
Tse, E. ;
Leung, A. Y. H. ;
Chim, C. -S. ;
Lie, A. K. W. ;
Kwong, Y. -L. .
INTERNAL MEDICINE JOURNAL, 2013, 43 (05) :541-546
[5]   Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia [J].
Collins, Curtis D. ;
Ellis, Jeffrey J. ;
Kaul, Daniel R. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (23) :2237-2243
[6]   Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].
Cornely, Oliver A. ;
Maertens, Johan ;
Winston, Drew J. ;
Perfect, John ;
Ullmann, Andrew J. ;
Walsh, Thomas J. ;
Helfgott, David ;
Holowiecki, Jerzy ;
Stockelberg, Dick ;
Goh, Yeow-Tee ;
Petrini, Mario ;
Hardalo, Cathy ;
Suresh, Ramachandran ;
Angulo-Gonzalez, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359
[7]   Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology [J].
Cornely, Oliver A. ;
Boehme, Angelika ;
Buchheidt, Dieter ;
Einsele, Hermann ;
Heinz, Werner J. ;
Karthaus, Meinolf ;
Krause, Stefan W. ;
Krueger, William ;
Maschmeyer, Georg ;
Penack, Olaf ;
Ritter, Joerg ;
Ruhnke, Markus ;
Sandherr, Michael ;
Sieniawski, Michal ;
Vehreschild, Joerg-Janne ;
Wolf, Hans-Heinrich ;
Ullmann, Andrew J. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01) :113-122
[8]   Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis [J].
Dranitsaris, George ;
Khoury, Haytham .
SUPPORTIVE CARE IN CANCER, 2011, 19 (11) :1807-1813
[9]  
Edejer T. Tan-Torres, 2003, MAKING CHOICES HLTH
[10]  
Gold M, 1996, COST EFFECTIVENESS H